Tumour infiltrating lymphocyte therapy(Cellular Therapeutics/Obsidian Therapeutics)

N/A

Report date: 2026/04/17 10:36:34

Base Information

Drug NameTumour infiltrating lymphocyte therapy(Cellular Therapeutics/Obsidian Therapeutics)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tumor Infiltrating Lymphocytes

Mechanisms of ActionImmunologic cytotoxicityLymphocyte replacements

TargetsNot applicable

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesObsidian Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesObsidian Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A